Reports on the role of NUAK2 in tumours of different origin vary: in melanoma, NUAK2 (SNARK) levels correlate negatively with patient survival (Namiki et al, 2011), whereas in ovarian cancer patients, an opposite trend was reported (Emmanuel et al, 2011). Here, NUAK2 is linked to melanoma.